...
首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection.
【24h】

Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection.

机译:基于透明质酸及其降解酶和降解产物的判别功能,用于区分慢性HCV感染的肝硬化患者与非肝硬化性肝病患者。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: The invasive liver biopsy is still considered the gold standard for assessing patients with chronic hepatitis C (CHC). Our aim was to determine the operating characteristics of a non-invasive index based on blood biomarkers for the prediction of cirrhosis in CHC patients. METHODS: Hyaluronic acid level was determined by radioimmuno-assay and its degrading enzymes and degradation products were determined by standard techniques in 153 patients with CHC with and without liver cirrhosis. Statistical analyses were performed by logistic regression, and receiver-operating characteristic (ROC) curves. RESULTS: The multivariate discriminant analysis (MDA) selected a function based on absolute values of five biochemical markers; Score=[1.63+Hyaluronic acid (microg/l)x0.001+N-acetyl-beta-d-glucosaminidase (micromol/ml/min)x0.02+glucuronic acid (microg/dl)x0.015+glucosamine (microg/dl)x0.006+AST/ALT ratiox0.04]. The selected MDA function correctly classified 96% of the cirrhotic patients at a discriminant cut-off score=2.5 (i.e. less than 2.5 indicated CHC without liver cirrhosis and greater than 2.5 indicated liver cirrhosis) with high degrees of sensitivity (95%) and specificity (97%). The positive predictive and negative predictive values were also high (95% and 97%, respectively). CONCLUSION: A patient with CHC can be simply and efficiently classified into cirrhotic or non-cirrhotic liver diseased patient using his or her MDA score.
机译:背景/目的:侵入性肝活检仍被认为是评估慢性丙型肝炎(CHC)患者的黄金标准。我们的目的是确定一种基于血液生物标志物的非侵入性指标的操作特征,以预测CHC患者的肝硬化。方法:采用放射免疫法测定153例患有和不患有肝硬化的CHC患者的透明质酸水平,并通过标准技术测定其降解酶和降解产物。通过logistic回归和接收者操作特征(ROC)曲线进行统计分析。结果:多元判别分析(MDA)基于五个生化标志物的绝对值选择了一个函数。得分= [1.63+透明质酸(微克/升)x0.001 + N-乙酰基-β-d-氨基葡萄糖苷酶(微摩尔/毫升/分钟)x0.02 +葡萄糖醛酸(微克/dl)x0.015+葡萄糖胺(微克/dl)x0.006+AST/ALT比x0.04]。所选的MDA功能可将96%的肝硬化患者正确分类,判别分值= 2.5(即小于2.5表示无肝硬化的CHC大于2.5表示肝硬化的C),具有高度的敏感性(95%)和特异性(97%)。阳性预测值和阴性预测值也很高(分别为95%和97%)。结论:使用MDA评分可以将CHC患者简单有效地分为肝硬化或非肝硬化肝病患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号